BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer

The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer that could see a return to the category for the drugmaker.